Dr. Paul Peter Tak
@paulpetertak
Physician-scientist. Professor. Former Chief Immunology Officer of GSK. CEO of Candel Therapeutics ($CADL). Views expressed here are my own. Likes≠endorsement.
To be very clear: I was never ‘hired’ by @SetPointMed, but I was indeed the International Principal Investigator for the first clinical trial ever to assess whether stimulating the inflammatory reflex (cholinergic anti-inflammatory pathway) by directly implanting an electronic…
🧵 Can the Nervous System Be Hacked? featuring Kevin Tracey @KevinJTraceyMD, Ralph Zitnik @SetPointMed, Paul Peter Tak @paulpetertak and Frieda Koopman
Throwback to Kyle's inspiring 2023 story on WCVB about how a clinical trial of CAN-3110 gave her ‘the gift of time’, living with glioblastoma. Her journey inspires us to advance CAN-3110 for recurrent high-grade glioma. Watch: wcvb.com/article/boston… #BrainCancer #GBMDay $CADL
That’s correct.
$CADL Here is a nice stat. % of biotech companies with stat sig phase 3 trial - hit primary & secondary endpoints done under SPA go on to get FDA approval? @paulpetertak CEO says it’s 92% in last video with @ideapharma. Looks spot on!!!!!
$CADL Great write-up that perfectly captures CADL's current situation. So if you want to update your CADL understanding or discover CADL for the first time, this is a must read. beyondspx.com/article/candel…
‘create new markets where you’re the only player’
Want to beat the competition? Stop competing. The Blue Ocean Strategy flips the game: Instead of fighting rivals in bloody red oceans, create new markets where you’re the only player. Apple and Tesla did it. Here’s how you can too. 👇
True statement
The problem isn’t the availability of scientific research. It’s the flood of people misinterpreting complex data with zero training and full confidence. Access to information is no longer the barrier. Understanding it is.
Another very successful week. Everything on track. Enjoy the weekend! $CADL
Thanks @Labiotech_eu for featuring us in a lung cancer companies article! CAN-2409 achieved 24.5 months median overall survival (mOS) in #NSCLC with an inadequate response to ICIs, markedly better than mOS in published control patients treated with chemo. labiotech.eu/best-biotech/l…
We're pleased to be added to multiple Russell Value indexes in 2025 reconstitution, including Russell 2500 Value, Small Cap Value, 2000 Value, Microcap Value & 3000E Value indexes. We also maintained our membership in the Russell 3000 Index. ir.candeltx.com/news-releases/… $CADL
More good news: Candel was added to the Russell 2500 Value® Index, Russell Small Cap Value® Index, Russell 2000 Value® Index, Russell Microcap Value® Index, and Russell 3000E® Value Index. Additionally, the Company maintained its membership in the broad-market Russell 3000®…
#ICYMI: @FierceBiotech highlighted our successful phase 3 prostate cancer trial. The study demonstrated a statistically significant 30% reduction in disease recurrence risk fiercebiotech.com/biotech/candel… #ProstateCancer $CADL
Totally agree. Doing what you say you will do is an important trust builder. People may not always understand the optimal timing of next steps, as they can’t see the whole picture of what management deals with. But they need to be able to trust that management will deliver.
As a CEO, the day to day work and mission (patients, team) is really rewarding and what drives so many of us. With that said, I sometimes see colleagues lose sight of the fact that we need to deliver what we promised to shareholders. What you told them you would do as close as…